Effects of Inferior Mesenteric Vein Flow in Patients With Cirrhosis

Size: px
Start display at page:

Download "Effects of Inferior Mesenteric Vein Flow in Patients With Cirrhosis"

Transcription

1 CLINICAL GASTROENTEROLOGY AND HEPATOLOGY 2013;11: Effects of Inferior Mesenteric Vein Flow in Patients With Cirrhosis HITOSHI MARUYAMA, HIDEHIRO KAMEZAKI, TAKAYUKI KONDO, TADASHI SEKIMOTO, TARO SHIMADA, MASANORI TAKAHASHI, HIDEHIRO OKUGAWA, and OSAMU YOKOSUKA Department of Gastroenterology and Hepatology, Chiba University Graduate School of Medicine, Inohana, Chuou-ku, Chiba, Japan BACKGROUND & AIMS: METHODS: RESULTS: CONCLUSIONS: The inferior mesenteric vein (IMV) is detected in more than 90% of computed tomography images. Little is known about the hemodynamic features of IMV as a collateral vessel in portal hypertension, or its effects in clinical presentation and outcome. We investigated the roles of the IMV in portal hemodynamics, clinical presentation, and outcomes of patients with cirrhosis. We performed a prospective study of 467 patients with cirrhosis (274 men; age, y). We assessed hemodynamics in the IMV using Doppler sonography and compared these data with patients clinical presentation and patient outcome. IMV was detected in 94 patients (20.1%); 51 patients had hepatopetal flow, 33 patients had hepatofugal flow, and 10 patients had to-and-fro flow. Those with hepatofugal flow had a significantly greater number of ascites than those with hepatopetal flow, higher Child classification (P [.004), and a higher incidence of decompensated liver (51.5% vs 27.5%; P [.015) and rectal varices (56.3% vs 13.3%; P [.013). The incidence of gastroesophageal varices was lower among those with hepatofugal flow (51.5%; P [.005) or to-and-fro flow (40%; P [.008) than those with hepatopetal flow (80.4%). IMV had similar effects after adjustment for liver function. There were no differences in the cumulative rates of survival during the median 17.2 months of follow-up evaluation, when the patients with and without IMV were stratified by Child classification. In patients with cirrhosis, hepatofugal flow of the IMV appears to increase the risk of ascites and liver decompensation but reduce the risk for gastroesophageal varices. Although IMV is associated with reduced liver function, it does not affect survival. Keywords: Hepatic Encephalopathy; Prognostic Factor; Marker; Imaging. Portal hypertension is characterized by a combination of increased outflow resistance in the liver and increased portal inflow from the splenic and splanchnic circulation. The development of portal-collateral pathways is one of the hemodynamic features of portal hypertension. Collateral circulation develops along with increased portal pressure, and the hepatic venous pressure gradient threshold for the development of portosystemic collaterals and esophageal varices may be as low as 10 mm Hg. 1,2 The severity of portal hypertension may affect the liver function reserve and the prognosis of cirrhosis patients. 3,4 The inferior mesenteric vein (IMV) is the vessel that carries blood derived from the embryologic hindgut, which extends from the distal transverse colon to the proximal rectum. 5 It originates anterior to the sacrum and runs toward the upper abdomen, passing posterior to the distal duodenum and anterior to the left renal vein and the superior mesenteric artery before communicating with the portal system. The main drainage route of the IMV is the splenic vein, followed by the superior mesenteric vein or the splenomesenteric confluence. The IMV also has been a target of surgical treatment for portal decompression. 6 Previous studies have reported that the IMV is a common vessel that is detected in more than 90% of computed tomography images. 7,8 The incidence and diameter of the IMV were similar between the control and cirrhosis groups. 9 However, reversed flow in the IMV is considered rare, 10 and little is known about the hemodynamic features of IMV as a collateral vessel involved with portal hypertension. Furthermore, the vessel s influence on clinical presentations and long-term outcomes has not been fully discussed. The purpose of this study was to investigate the significance of IMV to portal hemodynamics, clinical presentations, and prognosis in cirrhosis patients. Patients and Methods Study Design This prospective study was performed between April 2007 and March 2012, and it was approved by the ethical committee at our hospital. Informed written consent was obtained from all subjects. Consecutive patients in our Gastroenterology Department who met the following conditions were Abbreviations used in this paper: IMV, inferior mesenteric vein; MELD, model for end-stage liver disease by the AGA Institute /$

2 December 2013 INFERIOR MESENTERIC VEIN IN CIRRHOSIS 1649 potential candidates for the study: (1) cirrhosis patients with signs of portal hypertension, such as gastroesophageal varices diagnosed via routine endoscopy or bleeding/bleeding history, ascites detected via routine ultrasonography, and overt hepatic encephalopathy; and (2) patients who received Doppler ultrasonography for a detailed evaluation of portal hemodynamics. This examination was conducted for patients with compensated cirrhosis, such as those with varices without bleeding history and decompensated cirrhosis. The study also had the following exclusion criteria: (1) patients with hepatocellular carcinoma that was not controllable with nonsurgical treatment; (2) patients with a history of abdominal surgery; (3) patients who underwent partial splenic embolism or splenectomy; (4) patients who received antiviral treatment during the follow-up period; and (5) patients who received vasoactive medication, such as a b-blockers. Cirrhosis was diagnosed based on both biochemical findings and 2 different imaging findings (ultrasound and computed tomography/magnetic resonance imaging). A portal vein thrombus was defined as an echogenic area in the portal trunk, a main intrahepatic branch of the portal vein, the splenic vein, or the superior mesenteric vein detected with ultrasonography. Hepatic encephalopathy was graded according to the West Haven criteria, 11 and grades of II or higher were categorized as overt hepatic encephalopathy. Decompensated cirrhosis was defined by the detection of at least one of the following presentations: variceal bleeding, uncontrolled ascites, overt hepatic encephalopathy, spontaneous bacterial peritonitis, or jaundice (total bilirubin level, >3.0 mg/dl). The grade of ascites was defined according to the clinical and ultrasound findings: mild (þ) for ascites only detectable by ultrasound examination and moderate to severe (þþ) for ascites causing abdominal distension. Ultrasound An SSA-770A or 790A ultrasound system (Toshiba, Tokyo, Japan) with a 3.75-MHz convex probe was used in this study. All examinations were performed with the patient in the supine position after fasting for 4 hours or longer. The portal trunk was detected with a longitudinal or oblique scan of the upper abdomen. The IMV was detected on a long-axis view with the oblique scan slightly toward the left lower quadrant in the upper to middle abdomen. 5 The diameter of, and blood flow in, the portal trunk and the IMV were measured with the sampling width corresponding to the diameter of the vessel and at an angle less than 60 between the ultrasound beam and the vessel. The average value of measurements taken 2 or more times was calculated and used for analysis. All of the ultrasound examinations were performed by H.M. or M.T., each of whom had more than 8 years of experience. Endoscopy Routine or screening endoscopy was performed using GIF Q240 or Q260 endoscopes for upper gastrointestinal endoscopy and CF-H260AI or PCF-Q260AI endoscopes for colonoscopy (Olympus, Tokyo, Japan). We followed the Japan Research Society for Portal Hypertension s General Rules for Recording Endoscopic Findings for grading the endoscopic findings of gastroesophageal or rectal varices, as follows: F1 (small), F2 (medium), and F3 (large). 12 All endoscopic procedures were performed by H.M., H.O., M.T., T.S., T.S., or T.K. The study used endoscopic data that were obtained within 6 months before/after Doppler examination. Statistical Analysis All of the data were expressed as medians or means with the SD or as percentages. Continuous variables were compared using the Student t test, the Mann Whitney U test, or the Fisher protected least-significant-difference test. Categoric variables were compared using the chi-squared test. The patients survival times were based on the date of death, liver transplantation, or the final date during the study period on which the patient was confirmed to be alive. The Kaplan Meier method was used to calculate survival probabilities, and the difference was compared with the log-rank test. The primary comparison of the study was a comparison of patients with and without a detected IMV, and the secondary comparison was among 3 groups according to the flow direction in the IMV on Doppler sonogram (hepatopetal, to and fro, and hepatofugal) among patients with a detectable IMV. Statistical significance was defined as a P value of less than.05; however, the Bonferroni correction was used for multiple comparisons (3 groups), and a P value of less than.0166 was considered significant. Statistical analyses were performed using the SPSS software package (version 17.0; SPSS, Inc, Chicago, IL). Results Patients and Portal Hemodynamics The study consisted of 467 cirrhotic patients (Figure 1, Table 1). The IMV was detected in 20.1% (94 of 467) of the patients and had a mean diameter of mm (range, ). The flow direction was hepatopetal in 51 patients, hepatofugal in 33 patients, and to and fro in 10 patients. The IMVs with a hepatofugal flow direction had a mean diameter of mm (median, 6.6 mm; range, ), a flow velocity of cm/s (median, 10.9 cm/s; range, ), and a flow volume of ml/min (median, 230 ml/min; range, ). There was no difference in the diameter, velocity, and flow volume in the portal vein of patients with and without IMV. Reversed flow direction in the portal trunk was detected in 3 patients who had IMVs with a hepatofugal flow direction (hepatofugal IMV) and a flow volume higher than the median value of 230 ml/min. In addition, the diameter and flow volume in the portal trunk were lower in patients with a hepatofugal IMV greater than 230 ml/min (mean SD, mm; ml/min) than those with a hepatofugal IMV of 230 ml/min or less (mean SD, mm, P ¼.006; mean SD, ml/min, P ¼.02). The median follow-up period for all of the subjects was 17.2 months. Clinical Presentations There were significant differences in the clinical presentations depending on the flow direction in the IMV (Table 2). The patients with hepatofugal IMV showed more severe ascites (P ¼.006), a more severe Child classification (P ¼.004), a higher incidence of decompensated condition of the liver (17 of 33,

3 1650 MARUYAMA ET AL CLINICAL GASTROENTEROLOGY AND HEPATOLOGY Vol. 11, No. 12 Figure 1. Diagram for patient enrollment. According to the inclusion and exclusion criteria, there were 467 subjects in this study. 51.5%; vs 14 of 51, 27.5%; P ¼.015), and more frequent rectal varices (9 of 16, 56.3% vs 2 of 15, 13.3%; P ¼.013) compared with patients with IMVs with a hepatopetal flow direction (hepatopetal IMV). None of the patients presented with bleeding from rectal varices (median follow-up period, 17.5 mo). The incidence of gastroesophageal varices was lower in patients with hepatofugal IMV (17 of 33, 51.5%; P ¼.005) or to and fro IMV (4 of 10, 40%; P ¼.008) than in those with hepatopetal IMV (41 of 51, 80.4%). The clinical presentations were compared after the adjustment of liver function severity based on the model for end-stage liver disease (MELD) score (Table 3). The incidence of rectal varices was higher and the grade of ascites was worse in patients with hepatofugal/to-and-fro IMV than in those with hepatopetal IMV among the patients with a MELD score less than 10, or greater than 10 and less than 20. The incidence of gastroesophageal varices was lower in patients with hepatofugal IMV than in those with hepatofugal/to-and-fro IMV among the patients with a MELD score less than 10, or greater than 10 and less than 20. Overt hepatic encephalopathy was more frequent among patients with hepatofugal IMV greater than 230 ml/min (4 of 17; 23.5%) than those with hepatofugal IMV of 230 ml/min or less (0 of 16; P ¼.04; Table 4). The 4 patients with hepatofugal IMV greater than 230 ml/min developed overt hepatic encephalopathy despite taking oral medications that consisted of both nonabsorbable disaccharides and kanamycin monosulfate during the median observation period of 15.2 months (mean SD; ; range, 5 days to 60.4 mo). Neither the incidence of portal vein thrombosis nor bleeding/ treatment history of varices showed a significant relationship between the presence and absence of IMV or its flow direction (Tables 1 and 2). Prognosis Cumulative survival rates were compared in terms of the presence of IMV by stratifying the cohorts according to their Child classification (A, B, and C) because of the differences in the liver function reserve at baseline (Table 2). There were no significant differences in the cumulative survival rates of patients with hepatopetal IMV and hepatofugal/to-and-fro IMV in the cohorts classified as Child A (72.8% at 1 y, 59.1% at 3 y, and 59.1% at 5 y in patients with hepatopetal IMV; 83.3% at 1 y, 55.6% at 3 y, and 55.6% at 5 y in patients with hepatofugal/toand-fro IMV; P ¼.73), Child B (67.4% at 1 y and 19.6% at 3 y in patients with hepatopetal IMV; 65.23% at 1 y and 46.7% at 3 y in patients with hepatofugal/to-and-fro IMV; P ¼.62), or Child C (19.4% at 1 y in patients with hepatopetal IMV; 80% at 1 y in patients with hepatofugal/to-and-fro IMV; P ¼.34). There was also no significant difference in the ratio for concomitant hepatocellular carcinoma between the 2 groups (P ¼.51). Discussion We report the clinical significance of the IMV in patients with cirrhosis. As previously reported, the IMV may be a common vessel that is similar in healthy subjects and patients with cirrhosis because it reflects normal embryologic and anatomic development. 7 9 However, our study focused on the IMV as a collateral route in portal hypertension. The incidence of IMV based on Doppler sonography was 20.1% in cirrhosis showing various flow directions, and the mean diameter of the IMVs with a hepatofugal flow direction was 7.7 mm. One study reported that the IMV diameter was less than 6 mm on computed tomography images in normal subjects. Considering the presence of a hyperdynamic state in cirrhosis, the mean diameter of IMV in our study may be reasonable. 13 Meanwhile, the incidence of IMV may be much lower than that in previous reports. 7,8 The

4 December 2013 INFERIOR MESENTERIC VEIN IN CIRRHOSIS 1651 Table 1. Baseline Characteristics of the Patients IMV Absence Presence P value N Age, y Sex, male/female 219/154 55/39.97 Etiology C/A/NBNC/PBC/B/AIH/NASH/PSC/C 167/63/48/28/27/16/ 47/27/8/4/6/1/1/.26 þa/bþc/bþa/aihþa/pbcþaih 13/3/2/2/2/1/1 0/0/0/0/0/0 Platelet count, 10 4 /mm Child class, A/B/C 130/166/77 35/42/17.83 Child Pugh score Total bilirubin level, mg/dl Albumin level, g/dl Prothrombin time, % NH3, mg/ml NH3 in patients with Tx NH3 in patients without Tx MELD score Varices Gastroesophageal, -/þ 81/292 30/ Rectal, -/þ 101/27 22/12.09 Bleeding history from varices Prior treatment for varices Portal vein Diameter, mm Velocity, cm/s Volume, ml/min Portal vein thrombosis Spleen size, mm Ascites, -/þ/þþ 242/72/59 31/35/28 <.0001 HE, -/þ 348/25 85/9.34 Hepatic venous pressure gradient, mm H 2 O HE in patients with Tx, -/þ 103/16 8/9.35 Hepatocellular carcinoma, -/þ 238/135 60/34.99 Decompensated cirrhosis, -/þ 281/92 51/43 <.0001 NOTE. A comparison was made between patients with and without detected inferior mesenteric vein. -, absence; þ, presence. Grade of ascites: þ, ascites only detectable by ultrasound examination; þþ, ascites causing abdominal distension. A, alcohol; AIH, autoimmune hepatitis; B, hepatitis B virus; C, hepatitis C virus; HE, hepatic encephalopathy by West Haven criteria (overt hepatic encephalopathy for grade II or more); NASH, nonalcoholic steatohepatitis; NBNC, non-b non-c; PBC, primary biliary cirrhosis; PSC, primary sclerosing cholangitis; Tx, oral medication with nonabsorbable disaccharides and/or kanamycin monosulfate. presence of ascites and/or intestinal bloating caused by cirrhosis in some of the patients might have affected the detection of the vessel and flow signals by ultrasound. Nonetheless, there is a possibility of a false-negative result for IMV detection. Considering the recent improvement of detectability of color signals by ultrasonography, however, the influence of IMV on portal hemodynamics might be weak in patients without detection of IMV in our study. Collateral vessel formation may be linked closely to clinical presentation. First, our study examined the incidence and types of varices as IMV-related presentations. As expected, rectal varices were seen significantly more often in more than onethird of the patients with IMV and more than half of the patients with hepatofugal IMV. Next, the effect of IMV on the development of gastroesophageal varices was evaluated. A previous study based on a radionuclide examination via the rectum reported that an IMV-related portosystemic shunt did not prevent the formation of large varices and that the magnitude of blood flow through peripheral collaterals might reflect the risk of a variceal hemorrhage. 14 The results may be inconsistent with our data, which showed a significantly lower incidence of gastroesophageal varices in patients with IMV than in those without. The discrepancy may be explained by the different methods used; the data based on radionuclide behavior might have been influenced by the systemic circulation, whereas our study was based on the direct measurement of IMV. According to our data, because hemodynamics in the portal trunk are influenced by the hepatofugal flow in the IMV, the presence of IMV may offer some effects that suppress the development of gastroesophageal varices. Hepatic encephalopathy is a significant complication of chronic liver dysfunction and is related closely to the serum ammonia level. The key sources of circulating ammonia depend on the metabolism in the intestine, kidney, and striated muscle. 15 In particularly, urease-containing gut flora, such as Klebsiella and Proteus species in the intestine, are important sources of ammonia, and the blood in the mesenteric vein is rich in ammonia. Nevertheless, our study found no difference in the

5 1652 MARUYAMA ET AL CLINICAL GASTROENTEROLOGY AND HEPATOLOGY Vol. 11, No. 12 Table 2. Comparison of Baseline Characteristics in Patients With IMV IMV Hepatopetal To and fro Hepatofugal N Age, y Sex, male/female 30/21 4/6 21/12.84 Platelet count, 10 4 /mm Child, A/B/C 27/19/5 a 2/5/3 b 6/18/9 c.011 Child Pugh score MELD score Varices Gastroesophageal, -/þ 10/41 d 6/4 e 16/17 f.045 Rectal, -/þ 13/2 g 2/1 h 7/9 i.044 Bleeding history from varices Prior treatment for varices Portal vein Diameter, mm Velocity, cm/s Volume, ml/min Portal vein thrombosis Spleen size, mm Ascites, -/þ/þþ 33/13/5 j 5/4/1 k 10/14/9 l.03 HE, -/þ 46/5 10/0 29/4.52 Hepatic venous pressure gradient, mm H 2 O HE in patients with Tx, -/þ 20/5 7/0 11/4.33 Hepatocellular carcinoma, -/þ 30/21 7/3 23/10.55 Decompensated cirrhosis, -/þ 37/14 o 8/2 m 16/17 n.03 NOTE. A comparison was made among 3 groups according to the flow direction in the inferior mesenteric vein on Doppler sonogram (hepatopetal, to and fro, and hepatofugal) among patients with a detectable inferior mesenteric vein. -, absence; þ, presence. Grade of ascites: þ, ascites only detectable by ultrasound examination; þþ, ascites causing abdominal distension. Child: a vs b, P ¼.09; a vs c, P ¼.004; b vs c, P ¼.97. Gastroesophageal varices: d vs e, P ¼.008; d vs f, P ¼.005; e vs f, P ¼.52. Rectal varices: g vs h, P ¼.4; g vs i, P ¼.013; h vs i, P ¼.47. Ascites: j vs k, P ¼.63; j vs l, P ¼.006; k vs l, P ¼.4. Decompensated cirrhosis: o vs m, P ¼.71; o vs n, P ¼.015; m vs n, P ¼.79. A, alcohol; AIH, autoimmune hepatitis; B, hepatitis B virus; C, hepatitis C virus; HE, hepatic encephalopathy by West Haven criteria (overt hepatic encephalopathy for grade II or more); NASH, nonalcoholic steatohepatitis; NBNC, non-b non-c; PBC, primary biliary cirrhosis; PSC, primary sclerosing cholangitis; Tx, oral medication with nonabsorbable disaccharides and/or kanamycin monosulfate. P value Table 3. Comparison of Clinical Presentations Based on the Adjustment of Liver Function (MELD Score) MELD clinical presentation Hepatopetal (n ¼ 51) To and fro (n ¼ 10) Hepatofugal (n ¼ 33) P value 10 (n ¼ 31) Gastroesophageal varices, -/þ 1/16 a 1/1 b 6/6 c.02 Rectal varices, -/þ 6/0 d 1/0 e 2/4 f.034 Ascites, -/þ/þþ 15/2/0 g 0/2/0 h 2/6/4 i.0004 Hepatic encephalopathy, -/þ 17/0 2/0 12/0 - >10 to 20 (n ¼ 47) Gastroesophageal varices, -/þ 6/20 j 4/1 k 10/6 l.009 Rectal varices, -/þ 6/1 m 0/1 n 1/5 o.027 Ascites, -/þ/þþ 18/7/1 p 0/1/4 q 4/6/6 r.0006 Hepatic encephalopathy, -/þ 25/1 5/0 15/1.82 >20 (n ¼ 16) Gastroesophageal varices, -/þ 3/5 1/2 0/5.29 Rectal varices, -/þ 1/1 1/0 4/0.23 Ascites, -/þ/þþ 6/1/1 s 0/1/2 t 0/1/4 u.038 Hepatic encephalopathy, -/þ 4/4 3/0 2/3.22 NOTE. A comparison was made among 3 groups according to the flow direction in the inferior mesenteric vein on Doppler sonogram (hepatopetal, to and fro, and hepatofugal) among patients with a detectable inferior mesenteric vein. -, absence; þ, presence. Grade of ascites: þ, ascites only detectable by ultrasound examination; þþ, ascites causing abdominal distension. Gastroesophageal varices: a vs b, P ¼.055; a vs c, P ¼.006; b vs c, P ¼ NS; j vs k, P ¼.013; j vs l, P ¼.011; k vs l, P ¼.47. Rectal varices: d vs e, P ¼ NS; d vs f, P ¼.014; e vs f, P ¼.21; m vs n, P ¼.06; m vs o, P ¼.013; n vs o, P ¼.66. Ascites: g vs h, P ¼ NS; g vs i, P ¼.0004; h vs i, P ¼.42; p vs q, P <.0001; p vs r, P ¼.0045; q vs r, P ¼.22; s vs t, P ¼.08; s vs u, P ¼.023; t vs u, P ¼ NS.

6 December 2013 INFERIOR MESENTERIC VEIN IN CIRRHOSIS 1653 Table 4. Comparison of Clinical Data in Patients With IMV Showing Hepatofugal Flow Direction IMV 230 ml/min a >230 ml/min a P value N Age, y Sex, male/female 10/6 9/8.58 Platelet count, 10 4 /mm Child score Total bilirubin, mg/dl Albumin, g/dl Prothrombin time, % NH3, mg/dl MELD score Varices Gastroesophageal, -/þ 6/10 11/6.12 Rectal, b -/þ 5/3 2/5.19 Spleen size, mm Portal trunk F/to-and-fro/R 15/1/0 13/1/3.21 Diameter, mm Velocity, cm/s Volume, ml/min Ascites, -/þ/þþ 2/14 7/10.06 HE, 0 I/IIwV 16/0 13/4.04 NOTE. Grade of ascites: þ, ascites only detectable by ultrasound examination; þþ, ascites causing abdominal distension. F, forward; HE, hepatic encephalopathy by West Haven criteria (overt hepatic encephalopathy for grade II or more); MELD, model for end-stage liver disease; R, reverse. a A rate of 230 ml/min is the median flow volume in the IMV with hepatofugal flow direction. b Rectal varices were evaluated in patients who received a colonoscopy within 6 months before/after Doppler study. risk of developing overt hepatic encephalopathy with respect to the presence/absence of IMV. However, overt hepatic encephalopathy was significantly more common in patients with advanced IMV (flow volume >230 ml/min) than in other patients, probably because of the carrier effect of blood flow with a high level of ammonia entering into the systemic circulation without passing though the liver. All 4 of these patients suffered from treatment-resistive presentations, suggesting the need for interventional control of the blood flow in the IMV. Decompensated conditions in the liver and severe ascites were significantly more common in patients with IMV than in those without IMV and in patients with hepatofugal IMV than in those with hepatopetal IMV. One possibility for these results is the inefficient use of blood flow from the intestine; that is, the IMV acts as a bypass for intestinal blood flow with a high nutritional content, which intrinsically should be carried into the liver, and it also acts as a route to release harmful components, such as endotoxin, into the systemic circulation. 16,17 Such disadvantageous behaviors of intestinal blood may account for the close relationship between IMV and poor liver function. Portal vein thrombosis represents considerable complication in cirrhosis. Our study did not find a significant relationship between development of IMV and incidence of portal vein thrombosis at baseline. However, presence of IMV might affect the cumulative occurrence rate of portal vein thrombosis in long-term observation due to the potential poor liver function in patients with IMV. Also, it should be examined whether IMV may have some effects on anticoagulation for portal vein thrombosis, which is an emerging trend in the literature. 19,20 There were some limitations to our study. First, this study did not take into account the outflow route of IMV because it is hard for Doppler ultrasonography to detect the outflow vessel. IMV flow drains into the internal iliac vein, gonadal vein, or directly to the inferior vena cava, 10,18 and these different types of shunt formations might represent different clinical presentations. Second, data for rectal varices were not acquired from all subjects, in some cases because colonoscopy is not a routine examination for patients with cirrhosis and in other cases because the patient declined the procedure. Furthermore, some data were not used because of the maximum elapsed time we permitted between the Doppler study and colonoscopy. Thus, the incidence of rectal varices and its relationship with IMV hemodynamics needs to be validated in future studies with a large patient population. In conclusion, the IMV has 2 opposing effects as a collateral vessel in cirrhosis: it promotes the development of rectal varices and hepatic encephalopathy, and it reduces the patient s chance of developing gastroesophageal varices. Although the presence of IMV was associated closely with poor liver function, it did not appear to have a significant influence on the prognosis in cirrhosis patients. It remains to be determined whether therapeutic radiologic intervention for IMV may have a positive effect on patients. References 1. Groszmann RJ, Garcia-Tsao G, Bosch J, et al. Beta-blockers to prevent gastroesophageal varices in patients with cirrhosis. N Engl J Med 2005;353: Garcia-Tsao G, Groszmann RJ, Fisher RL, et al. Portal pressure, presence of gastroesophageal varices and variceal bleeding. Hepatology 1985;5: Ripoll C, Groszmann R, Garcia-Tsao G, et al. Hepatic venous pressure gradient predicts clinical decompensation in patients with compensated cirrhosis. Gastroenterology 2007;133: Abraldes JG, Villanueva C, Banares R, et al. Hepatic venous pressure gradient and prognosis in patients with acute variceal bleeding treated with pharmacologic and endoscopic therapy. J Hepatol 2008;48: Wachsberg RH. Inferior mesenteric vein: gray-scale and Doppler sonographic findings in normal subjects and in patients with portal hypertension. AJR Am J Roentgenol 2005;184: Warren WD, Milliken WJ, Henderson JM, et al. Ten years of portal hypertensive surgery at Emory: results and new perspective. Ann Surg 1982;195: Graf O, Boland GW, Kaufman JA, et al. Anatomic variants of mesenteric veins: depiction with helical CT venography. AJR Am J Roentgenol 1997;168: Sakaguchi T, Suzuki S, Morita Y, et al. Analysis of anatomic variants of mesenteric veins by 3-dimensional portography using multidetectorrow computed tomography. Am J Surg 2010;200: Ito K, Blasbalg R, Hussain SM, et al. Portal vein and its tributaries: evaluation with thin-section three-dimensional contrast-enhanced dynamic fat-suppressed MR imaging. Radiology 2000;215: Akpinar E, Turkbey B, Karcaaltincaba M, et al. MDCT of inferior mesenteric vein: normal anatomy and pathology. Clin Radiol 2008; 63: Ferenci P, Lockwood A, Mullen K, et al. Hepatic encephalopathydefinition, nomenclature, and quantification: final report of the working party at the 11th World Congress of Gastroenterology, Vienna, Hepatology 2002;35:

7 1654 MARUYAMA ET AL CLINICAL GASTROENTEROLOGY AND HEPATOLOGY Vol. 11, No Tajiri T, Yoshida H, Obara K, et al. General rules for recording endoscopic findings of esophagogastric varices. Dig Endosc 2010;22: Shapir J, Rubin J. CT appearance of the inferior mesenteric vein. J Comput Assist Tomogr 1984;8: Hartleb M, Boldys H, Rudzki K, et al. Portal shunting in inferior mesenteric vein in cirrhosis: correlation with hemorrhage from esophageal varices. Am J Gastroenterol 1994;89: Olde Damink SW, Deutz NE, Dejong CH, et al. Interorgan ammonia metabolism in liver failure. Neurochem Int 2002;41: Wiest R, Garcia-Tsao G. Bacterial translocation (BT) in cirrhosis. Hepatology 2005;41: Bellot P, Frances R, Such J. Pathological bacterial translocation in cirrhosis: pathophysiology, diagnosis and clinical implications. Liver Int 2013;33: Matsumoto S, Mori H, Sagara Y, et al. Inferior mesenteric veno-caval shunt: imaging features and interventional treatment. Clin Radiol 2007;62: Amitrano L, Guardascione MA, Menchise A, et al. Safety and efficacy of anticoagulation therapy with low molecular weight heparin for portal vein thrombosis in patients with liver cirrhosis. J Clin Gastroenterol 2010;44: Delgado MG, Seijo S, Yepes I, et al. Efficacy and safety of anticoagulation on patients with cirrhosis and portal vein thrombosis. Clin Gastroenterol Hepatol 2012;10: Reprint requests Address requests for reprints to: Hitoshi Maruyama, MD, PhD, Department of Gastroenterology and Hepatology, Chiba University Graduate School of Medicine, 1-8-1, Inohana, Chuou-ku, Chiba, , Japan. maru-cib@umin.ac.jp; fax: (81) Conflicts of interest The authors disclose no conflicts.

Medicine. Differential Clinical Impact of Ascites in Cirrhosis and Idiopathic Portal Hypertension

Medicine. Differential Clinical Impact of Ascites in Cirrhosis and Idiopathic Portal Hypertension Medicine OBSERVATIONAL STUDY Differential Clinical Impact of Ascites in Cirrhosis and Idiopathic Portal Hypertension Hitoshi Maruyama, MD, PhD, Takayuki Kondo, MD, PhD, Tadashi Sekimoto, MD, PhD, and Osamu

More information

Cirrhosis and Portal Hypertension Gastroenterology Teaching Project American Gastroenterological Association

Cirrhosis and Portal Hypertension Gastroenterology Teaching Project American Gastroenterological Association CIRRHOSIS AND PORTAL HYPERTENSION Cirrhosis and Portal Hypertension Gastroenterology Teaching Project American Gastroenterological Association WHAT IS CIRRHOSIS? What is Cirrhosis? DEFINITION OF CIRRHOSIS

More information

Spontaneous portosystemic venous shunts in liver cirrhosis: Anatomy, pathophysiology, hemodynamic changes and imaging findings

Spontaneous portosystemic venous shunts in liver cirrhosis: Anatomy, pathophysiology, hemodynamic changes and imaging findings Spontaneous portosystemic venous shunts in liver cirrhosis: Anatomy, pathophysiology, hemodynamic changes and imaging findings Poster No.: C-3193 Congress: ECR 2010 Type: Educational Exhibit Topic: Vascular

More information

PORTAL HYPERTENSION. Tianjin Medical University LIU JIAN

PORTAL HYPERTENSION. Tianjin Medical University LIU JIAN PORTAL HYPERTENSION Tianjin Medical University LIU JIAN DEFINITION Portal hypertension is present if portal venous pressure exceeds 10mmHg (1.3kPa). Normal portal venous pressure is 5 10mmHg (0.7 1.3kPa),

More information

ORIGINAL ARTICLES LIVER, PANCREAS AND BILIARY TRACT

ORIGINAL ARTICLES LIVER, PANCREAS AND BILIARY TRACT CLINICAL GASTROENTEROLOGY AND HEPATOLOGY 2008;6:1129 1134 ORIGINAL ARTICLES LIVER, PANCREAS AND BILIARY TRACT Spleen Enlargement on Follow-Up Evaluation: A Noninvasive Predictor of Complications of Portal

More information

Incidence, Prevalence, and Clinical Significance of Abnormal Hematologic Indices in Compensated Cirrhosis

Incidence, Prevalence, and Clinical Significance of Abnormal Hematologic Indices in Compensated Cirrhosis CLINICAL GASTROENTEROLOGY AND HEPATOLOGY 2009;xx:xxx 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53

More information

CORRELATION OF PORTAL VEIN PULSATILITY PATTERN AND SEVERITY OF LIVER DISEASE IN PATIENTS WITH CIRRHOSIS AND PORTAL HYPERTENSION

CORRELATION OF PORTAL VEIN PULSATILITY PATTERN AND SEVERITY OF LIVER DISEASE IN PATIENTS WITH CIRRHOSIS AND PORTAL HYPERTENSION CORRELATION OF PORTAL VEIN PULSATILITY PATTERN AND SEVERITY OF LIVER DISEASE IN PATIENTS WITH CIRRHOSIS AND PORTAL HYPERTENSION Anish Subedee, Benu Lohani, Shashi Sharma Abstract: Objective: To correlate

More information

Ultrasound assessment of coronary veins as non-invasive marker for esophageal varices

Ultrasound assessment of coronary veins as non-invasive marker for esophageal varices Ultrasound assessment of coronary veins as non-invasive marker for esophageal varices Poster No.: C-1657 Congress: ECR 2011 Type: Scientific Exhibit Authors: R. Castellón Siles, A. Thomas, X. Serres, O.

More information

Editorial Process: Submission:07/25/2018 Acceptance:10/19/2018

Editorial Process: Submission:07/25/2018 Acceptance:10/19/2018 RESEARCH ARTICLE Editorial Process: Submission:07/25/2018 Acceptance:10/19/2018 Clinical Outcome and Predictive Factors of Variceal Bleeding in Patients with Hepatocellular Carcinoma in Thailand Jitrapa

More information

The Yellow Patient. Dr Chiradeep Raychaudhuri, Consultant Hepatologist, Hull University Teaching Hospitals NHS Trust

The Yellow Patient. Dr Chiradeep Raychaudhuri, Consultant Hepatologist, Hull University Teaching Hospitals NHS Trust The Yellow Patient Dr Chiradeep Raychaudhuri, Consultant Hepatologist, Hull University Teaching Hospitals NHS Trust there s a yellow patient in bed 40. It s one of yours. Liver Cirrhosis Why.When.What.etc.

More information

ORIGINAL ARTICLES LIVER, PANCREAS, AND BILIARY TRACT

ORIGINAL ARTICLES LIVER, PANCREAS, AND BILIARY TRACT CLINICAL GASTROENTEROLOGY AND HEPATOLOGY 2009;7:689 695 ORIGINAL ARTICLES LIVER, PANCREAS, AND BILIARY TRACT Incidence, Prevalence, and Clinical Significance of Abnormal Hematologic Indices in Compensated

More information

Variceal bleeding. Mainz,

Variceal bleeding. Mainz, Variceal bleeding Mainz, 21.09.2008 Risk of complications 5 years 10 years Ascites 10 % 25 % HCC 10 % 25 % Bleeding < 5 % 5-10 % Enceph. < 5 % < 5 % Typical situation : Mortality 10 % to 40 % Sequence

More information

Beta-blockers in cirrhosis: Cons

Beta-blockers in cirrhosis: Cons Beta-blockers in cirrhosis: Cons Eric Trépo MD, PhD Dept. of Gastroenterology. Hepatopancreatology and Digestive Oncology. C.U.B. Hôpital Erasme. Université Libre de Bruxelles. Bruxelles. Belgium Laboratory

More information

Transjugular Intrahepatic Portosystemic Shunt Reduction for Management of Recurrent Hepatic Encephalopathy

Transjugular Intrahepatic Portosystemic Shunt Reduction for Management of Recurrent Hepatic Encephalopathy CLINICAL IMAGES Ochsner Journal 17:311 316, 2017 Ó Academic Division of Ochsner Clinic Foundation Transjugular Intrahepatic Portosystemic Shunt Reduction for Management of Recurrent Hepatic Encephalopathy

More information

Surgical Rescue of Surgical Failures

Surgical Rescue of Surgical Failures HPB Surgery, 1999, Vol. 11, pp. 151-155 Reprints available directly from the publisher Photocopying permitted by license only (C) 1999 OPA (Overseas Publishers Association) N.V. Published by license under

More information

Management of Cirrhosis Related Complications

Management of Cirrhosis Related Complications Management of Cirrhosis Related Complications Ke-Qin Hu, MD, FAASLD Professor of Clinical Medicine Director of Hepatology University of California, Irvine Disclosure I have no disclosure related to this

More information

The Value of Renal Artery Resistive Indices: Association with

The Value of Renal Artery Resistive Indices: Association with The Value of Renal Artery Resistive Indices: Association with Esophageal Variceal Bleeding in Patients with Alcoholic Cirrhosis 1 Joo Nam Byun, M.D., Dong Hun Kim, M.D. Purpose: To determine whether resistive

More information

Evidence-Base Management of Esophageal and Gastric Varices

Evidence-Base Management of Esophageal and Gastric Varices Evidence-Base Management of Esophageal and Gastric Varices Rino Alvani Gani Hepatobiliary Division Department of Internal Medicine Faculty of Medicine Universitas Indonesia Cipto Mangunkusumo National

More information

Color Doppler Evaluation of Portal Venous System in Liver Diseases

Color Doppler Evaluation of Portal Venous System in Liver Diseases Original Article Print ISSN: 2321-6379 Online ISSN: 2321-595X DOI: 10.17354/ijss/2018/338 Color Doppler Evaluation of Portal Venous System in Liver Diseases Preeti Sharma 1, Sanjeev Sharma 2 1 Department

More information

Steps in Assessing Fibrosis 4/30/2015. Overview of Liver Disease Associated With HCV

Steps in Assessing Fibrosis 4/30/2015. Overview of Liver Disease Associated With HCV Overview of Liver Disease Associated With HCV Marion G. Peters, MD John V. Carbone, Endowed Chair Professor of Medicine Chief of Hepatology Research University of California San Francisco San Francisco,

More information

Carvedilol or Propranolol in the Management of Portal Hypertension?

Carvedilol or Propranolol in the Management of Portal Hypertension? Evidence Based Case Report Carvedilol or Propranolol in the Management of Portal Hypertension? Arranged by: dr. Saskia Aziza Nursyirwan RESIDENCY PROGRAM OF INTERNAL MEDICINE DEPARTMENT UNIVERSITY OF INDONESIA

More information

Index. Note: Page numbers of article titles are in boldface type.

Index. Note: Page numbers of article titles are in boldface type. Index Note: Page numbers of article titles are in boldface type. A Accelerated intravascular coagulation and fibrinolysis (AICF) in liver disease, 390 391 Acid suppression in liver disease, 403 404 ACLF.

More information

Esophageal Varices Beta-Blockers or Band Ligation. Cesar Yaghi MD Hotel-Dieu de France University Hospital Universite Saint Joseph

Esophageal Varices Beta-Blockers or Band Ligation. Cesar Yaghi MD Hotel-Dieu de France University Hospital Universite Saint Joseph Esophageal Varices Beta-Blockers or Band Ligation Cesar Yaghi MD Hotel-Dieu de France University Hospital Universite Saint Joseph Esophageal Varices Beta-Blockers or Band Ligation? Risk of esophageal variceal

More information

S planchnic vein thrombosis is not an uncommon

S planchnic vein thrombosis is not an uncommon 691 LIVER Splanchnic vein thrombosis in candidates for liver transplantation: usefulness of screening and anticoagulation C Francoz, J Belghiti, V Vilgrain, D Sommacale, V Paradis, B Condat, M H Denninger,

More information

Liver Transplantation

Liver Transplantation 1 Liver Transplantation Department of Surgery Yonsei University Wonju College of Medicine Kim Myoung Soo M.D. ysms91@wonju.yonsei.ac.kr http://gs.yonsei.ac.kr History Development of Liver transplantation

More information

MANAGEMENT OF LIVER CIRRHOSIS: PRACTICE ESSENTIALS AND PATIENT SELF-MANAGEMENT

MANAGEMENT OF LIVER CIRRHOSIS: PRACTICE ESSENTIALS AND PATIENT SELF-MANAGEMENT MANAGEMENT OF LIVER CIRRHOSIS: PRACTICE ESSENTIALS AND PATIENT SELF-MANAGEMENT Sherona Bau, ACNP The Pfleger Liver Institute 200 UCLA Medical Plaza, Suite 214 Los Angeles, CA 90095 September 30, 2017 I

More information

Etiology of liver cirrhosis

Etiology of liver cirrhosis Liver cirrhosis 1 Liver cirrhosis Liver cirrhosis is the progressive replacement of normal hepatic cells by fibrous scar tissue, This scarring is accompanied by the loss of viable hepatocytes, which are

More information

Evaluation of liver and spleen stiffness using a ultrasound guided method: Accuracy of ARFI(R) measurements in liver disease patients

Evaluation of liver and spleen stiffness using a ultrasound guided method: Accuracy of ARFI(R) measurements in liver disease patients Evaluation of liver and spleen stiffness using a ultrasound guided method: Accuracy of ARFI(R) measurements in liver disease patients Poster No.: C-3242 Congress: ECR 2010 Type: Topic: Authors: Keywords:

More information

Evaluation of liver and spleen stiffness using a ultrasound guided method: Accuracy of ARFI(R) measurements in liver disease patients

Evaluation of liver and spleen stiffness using a ultrasound guided method: Accuracy of ARFI(R) measurements in liver disease patients Evaluation of liver and spleen stiffness using a ultrasound guided method: Accuracy of ARFI(R) measurements in liver disease patients Poster No.: C-3242 Congress: ECR 2010 Type: Topic: Authors: Keywords:

More information

VARICEAL BLEEDING. Ram Subramanian MD Hepatology & Critical Care Medical Director of Liver Transplant Emory University, Atlanta.

VARICEAL BLEEDING. Ram Subramanian MD Hepatology & Critical Care Medical Director of Liver Transplant Emory University, Atlanta. VARICEAL BLEEDING Ram Subramanian MD Hepatology & Critical Care Medical Director of Liver Transplant Emory University, Atlanta Disclosures: None OUTLINE Pathophysiology of portal hypertension Splanchnic

More information

Detection of Esophageal Varices in Liver Cirrhosis Using Non-invasive Parameters

Detection of Esophageal Varices in Liver Cirrhosis Using Non-invasive Parameters ORIGINAL ARTICLE Detection of Esophageal Varices in Liver Cirrhosis Using Non-invasive Parameters Johana Prihartini*, LA Lesmana**, Chudahman Manan***, Rino A Gani** ABSTRACT Aim: recent guidelines recommend

More information

Index. Note: Page numbers of article titles are in boldface type.

Index. Note: Page numbers of article titles are in boldface type. Index Note: Page numbers of article titles are in boldface type. A Acute variceal bleeding management of, 251 262 balloon tamponade of esophagus in, 257 258 endoscopic therapies in, 255 257. See also Endoscopy,

More information

Obliterative hepatocavopathy ultrasound and cavography findings

Obliterative hepatocavopathy ultrasound and cavography findings doi:10.2478/v10019-008-0020-6 case report Obliterative hepatocavopathy ultrasound and cavography findings Ramazan Kutlu Department of Radiology, Inonu University School of Medicine, Malatya, Turkey ackgound.

More information

Guidelines, Policies and Statements D5 Statement on Abdominal Scanning

Guidelines, Policies and Statements D5 Statement on Abdominal Scanning Guidelines, Policies and Statements D5 Statement on Abdominal Scanning Disclaimer and Copyright The ASUM Standards of Practice Board have made every effort to ensure that this Guideline/Policy/Statement

More information

European. Young Hepatologists Workshop. Organized by : Quantification of fibrosis and cirrhosis outcomes

European. Young Hepatologists Workshop. Organized by : Quantification of fibrosis and cirrhosis outcomes supported by from Gilea Quantification of fibrosis and cirrhosis outcomes th 5 European 5 European Young Hepatologists Workshop Young Hepatologists Workshop August, 27-29. 2015, Moulin de Vernègues Vincenza

More information

Noncirrhotic Portal Hypertension: Imaging, Hemodynamics, and Endovascular Therapy

Noncirrhotic Portal Hypertension: Imaging, Hemodynamics, and Endovascular Therapy REVIEW Noncirrhotic Portal Hypertension: Imaging, Hemodynamics, and Endovascular Therapy Venkatesh P. Krishnasamy, M.D.,* Michael J. Hagar, M.D., Albert K. Chun, M.D., M.B.A., and Elliot Levy, M.D. Patients

More information

Michele Bettinelli RN CCRN Lahey Health and Medical Center

Michele Bettinelli RN CCRN Lahey Health and Medical Center Michele Bettinelli RN CCRN Lahey Health and Medical Center Differentiate the types of varices Identify glue preparations utilized when treating gastric varices Review the process of glue administration

More information

Management of Portal Vein Thrombosis With and Without Cirrhosis

Management of Portal Vein Thrombosis With and Without Cirrhosis Management of Portal Vein Thrombosis With and Without Cirrhosis Dominique-Charles Valla Service d Hépatologie,Hôpital Beaujon, APHP, Université Paris-Diderot, Inserm CRB3 Extrahepatic Portal Vein Obstruction

More information

Diagnostic Procedures. Measurement of Hepatic venous pressure in management of cirrhosis. Clinician s opinion

Diagnostic Procedures. Measurement of Hepatic venous pressure in management of cirrhosis. Clinician s opinion 5 th AISF Post-Meeting Course Diagnostic and Therapeutic Invasive Procedures in Hepatology Rome, February 25 th Diagnostic Procedures Measurement of Hepatic venous pressure in management of cirrhosis Clinician

More information

Title: Cholestasis after TIPS placement in a patient with primary sclerosing cholangitis: an uncommon complication

Title: Cholestasis after TIPS placement in a patient with primary sclerosing cholangitis: an uncommon complication Title: Cholestasis after TIPS placement in a patient with primary sclerosing cholangitis: an uncommon complication Authors: Alejandro Salagre García, Carolina Muñoz Codoceo, Elena Gómez Domínguez, Inmaculada

More information

Lab Monitor Images Dissection of the Abdominal Vasculature + Lower Digestive System

Lab Monitor Images Dissection of the Abdominal Vasculature + Lower Digestive System Lab Monitor Images Dissection of the Abdominal Vasculature + Lower Digestive System Stomach & Duodenum Frontal (AP) View Nasogastric tube 2 1 3 4 Stomach Pylorus Duodenum 1 Duodenum 2 Duodenum 3 Duodenum

More information

Investigations before OLT, Immunosuppression and rejection, Follow up after OLT.

Investigations before OLT, Immunosuppression and rejection, Follow up after OLT. Investigations before OLT, Immunosuppression and rejection, Follow up after OLT andrea.degottardi@insel.ch When is liver transplantation indicated? When is liver transplantation indicated? Frequent: CIRRHOSIS

More information

Title: Lower gastrointestinal bleeding as a form of presentation in an adult case of Abernethy syndrome

Title: Lower gastrointestinal bleeding as a form of presentation in an adult case of Abernethy syndrome Title: Lower gastrointestinal bleeding as a form of presentation in an adult case of Abernethy syndrome Authors: Aida Suárez Sánchez, Lorena Solar García, Carmen María García Bernardo, Alberto Miyar de

More information

PORTAL HYPERTENSION An Introduction to the Culprit of Many Liver Failure Complications

PORTAL HYPERTENSION An Introduction to the Culprit of Many Liver Failure Complications PORTAL HYPERTENSION An Introduction to the Culprit of Many Liver Failure Complications Edy G. Trujillo, RN, MSN, ACNP-BC Liver Transplant RRUCLA Medical Center July 31, 2018 What Do We All Look Forward

More information

Liver Ultrasound - Beyond the Basics. Pamela Parker Lead Sonographer

Liver Ultrasound - Beyond the Basics. Pamela Parker Lead Sonographer Liver Ultrasound - Beyond the Basics Pamela Parker Lead Sonographer Aims Review what we know about the liver Reasons for imaging Focal lesions Diffuse disease Can we do more? The Liver The Liver The Liver

More information

Controversies in Management of Portal Hypertension and Cirrhosis Complications in the Transplant Candidate

Controversies in Management of Portal Hypertension and Cirrhosis Complications in the Transplant Candidate Controversies in Management of Portal Hypertension and Cirrhosis Complications in the Transplant Candidate Patrick Northup, MD, FAASLD, FACG Medical Director, Liver Transplantation University of Virginia

More information

following the last documented transfusion; thereafter, evaluate the residual impairment(s).

following the last documented transfusion; thereafter, evaluate the residual impairment(s). Adult Listings 5.01 Category of Impairments, Digestive System 5.02 Gastrointestinal hemorrhaging from any cause, requiring blood transfusion (with or without hospitalization) of at least 2 units of blood

More information

EDUCATION PRACTICE. Management of Refractory Ascites. Clinical Scenario. The Problem

EDUCATION PRACTICE. Management of Refractory Ascites. Clinical Scenario. The Problem CLINICAL GASTROENTEROLOGY AND HEPATOLOGY 2005;3:1187 1191 EDUCATION PRACTICE Management of Refractory Ascites ANDRÉS CÁRDENAS and PERE GINÈS Liver Unit, Institute of Digestive Diseases, Hospital Clínic,

More information

King Abdul-Aziz University Hospital (KAUH) is a tertiary

King Abdul-Aziz University Hospital (KAUH) is a tertiary Modelling Factors Causing Mortality in Oesophageal Varices Patients in King Abdul Aziz University Hospital Sami Bahlas Abstract Objectives: The objective of this study is to reach a model defining factors

More information

BETA-BLOCKERS IN CIRRHOSIS.PRO.

BETA-BLOCKERS IN CIRRHOSIS.PRO. BETA-BLOCKERS IN CIRRHOSIS.PRO. Angela Puente Sánchez. MD PhD Hepatology Unit. Gastroenterology department Marques de Valdecilla University Hospital. Santander INTRODUCTION. Natural history of cirrhosis

More information

ESLD a Guide for HIV Physicians. Marion Peters University of California San Francisco June 2015

ESLD a Guide for HIV Physicians. Marion Peters University of California San Francisco June 2015 ESLD a Guide for HIV Physicians Marion Peters University of California San Francisco June 2015 Disclosures Honararia from Johnson and Johnson Roche Merck Gilead Spouse employee of Hoffman La Roche Natural

More information

Home Intravenous Antibiotic Treatment for Intractable Cholangitis in Biliary Atresia

Home Intravenous Antibiotic Treatment for Intractable Cholangitis in Biliary Atresia Home Intravenous Antibiotic Treatment for Intractable Cholangitis in Biliary Atresia Hye Kyung Chang, Jung-Tak Oh, Seung Hoon Choi, Seok Joo Han Division of Pediatric Surgery, Department of Surgery, Yonsei

More information

Original Article PLATELET COUNT TO SPLEEN DIAMETER RATIO AS A PREDICTOR OF ESOPHAGEAL VARICES IN PATIENTS OF LIVER CIRRHOSIS DUE TO HEPATITIS C VIRUS

Original Article PLATELET COUNT TO SPLEEN DIAMETER RATIO AS A PREDICTOR OF ESOPHAGEAL VARICES IN PATIENTS OF LIVER CIRRHOSIS DUE TO HEPATITIS C VIRUS Original Article AS A PREDICTOR OF ESOPHAGEAL VARICES IN PATIENTS OF LIVER CIRRHOSIS DUE TO HEPATITIS C VIRUS Khalid Amin 1, Dilshad Muhammad 2, Amin Anjum 3, Kashif Jamil 4, Ali Hassan 5 1 Associate Professor

More information

Update in abdominal Surgery in cirrhotic patients

Update in abdominal Surgery in cirrhotic patients Update in abdominal Surgery in cirrhotic patients Safi Dokmak HBP department and liver transplantation Beaujon Hospital, Clichy, France Cairo, 5 April 2016 Cirrhosis Prevalence in France (1%)* Patients

More information

Emricasan (IDN-6556) administered orally for 28 days lowers portal pressure in patients with compensated cirrhosis and severe portal hypertension

Emricasan (IDN-6556) administered orally for 28 days lowers portal pressure in patients with compensated cirrhosis and severe portal hypertension Emricasan (IDN-6556) administered orally for 28 days lowers portal pressure in patients with compensated cirrhosis and severe portal hypertension Guadalupe Garcia-Tsao, Michael Fuchs, Mitchell Shiffman,

More information

ACG & AASLD Joint Clinical Guideline: Prevention and Management of Gastroesophageal Varices and Variceal Hemorrhage in Cirrhosis

ACG & AASLD Joint Clinical Guideline: Prevention and Management of Gastroesophageal Varices and Variceal Hemorrhage in Cirrhosis ACG & AASLD Joint Clinical Guideline: Prevention and Management of Gastroesophageal Varices and Variceal Hemorrhage in Cirrhosis Guadalupe Garcia-Tsao, M.D., 1 Arun J. Sanyal, M.D., 2 Norman D. Grace,

More information

Supplemental Tables. Parasitic Schistosomiasis increase < 1. Genetic Hemochromatosis increase < 1. autoimmune Autoimmune hepatitis (AIH) increase < 1

Supplemental Tables. Parasitic Schistosomiasis increase < 1. Genetic Hemochromatosis increase < 1. autoimmune Autoimmune hepatitis (AIH) increase < 1 Supplemental Tables Supplemental Table 1 Various etiologies of liver cirrhosis and their association with liver stiffness and AST/ALT ratio Disease category Cause Example LS AST/ALT Inflammatory liver

More information

End-Stage Liver Disease (ESLD): A Guide for HIV Physicians

End-Stage Liver Disease (ESLD): A Guide for HIV Physicians Slide 1 of 32 End-Stage Liver Disease (ESLD): A Guide for HIV Physicians Marion G. Peters, MD John V. Carbone, MD, Endowed Chair Professor of Medicine Chief of Hepatology Research University of California

More information

CLINICAL How Should a Hospitalized Patient with Newly Diagnosed Cirrhosis Be Evaluated and Managed?

CLINICAL How Should a Hospitalized Patient with Newly Diagnosed Cirrhosis Be Evaluated and Managed? CLINICAL How Should a Hospitalized Patient with Newly Diagnosed Cirrhosis Be Evaluated and Managed? The Hospitalist. 2016 August;2016(8) Author(s): Raj Sehgal, MD; Joshua Hanson, MD, MPH; Division OF The

More information

Thrombocytopenia and Chronic Liver Disease

Thrombocytopenia and Chronic Liver Disease Thrombocytopenia and Chronic Liver Disease Severe thrombocytopenia (platelet count

More information

Treating patients with end-stage liver disease: Are we ready? Dr. Mino R. Mitri, M.D., C.M., M.Ed., FRCPC

Treating patients with end-stage liver disease: Are we ready? Dr. Mino R. Mitri, M.D., C.M., M.Ed., FRCPC Treating patients with end-stage liver disease: Are we ready? Dr. Mino R. Mitri, M.D., C.M., M.Ed., FRCPC mino.mitri@ubc.ca No Conflict of Interest 157 patients 157 patients 6 transplanted Criteria Liver

More information

Portal vein stent placement for the treatment of postoperative portal vein stenosis: long-term success and factor associated with stent failure

Portal vein stent placement for the treatment of postoperative portal vein stenosis: long-term success and factor associated with stent failure Kato et al. BMC Surgery (2017) 17:11 DOI 10.1186/s12893-017-0209-y RESEARCH ARTICLE Portal vein stent placement for the treatment of postoperative portal vein stenosis: long-term success and factor associated

More information

Visceral Vascular Ultrasound. Joel Thompson, MD, MPH Borg & Ide Imaging

Visceral Vascular Ultrasound. Joel Thompson, MD, MPH Borg & Ide Imaging Visceral Vascular Ultrasound Joel Thompson, MD, MPH Borg & Ide Imaging Objectives: Review major abdominal vascular structures Identify normal peak systolic velocity (PSV) for major abdominal arteries.

More information

Non tumoral portal vein thrombosis during cirrhosis: Should anticoagulation be proposed?

Non tumoral portal vein thrombosis during cirrhosis: Should anticoagulation be proposed? Full Text Article Open Access Original Article Non tumoral portal vein thrombosis during cirrhosis: Should anticoagulation be proposed? Bibani Norsaf 1,2, Trad Dorra 1,2*, Bejaoui Mohamed 1,2, Sabbeh Mariem

More information

Methods. Research Article Kobayashi, Maruyama, Kiyono, Ogasawara, Suzuki, et al.

Methods. Research Article Kobayashi, Maruyama, Kiyono, Ogasawara, Suzuki, et al. Research Article CLINICAL INVESTIGATION Constraining Effect of Mild Portal Hypertension against the Negative Influence of Muscle Mass Loss in Cirrhosis after Esophageal Variceal Eradication Abstract Background:

More information

Evaluation of Clinical, Biochemical and Ultrasound Parameters in Diagnosis of Oesophageal Varices

Evaluation of Clinical, Biochemical and Ultrasound Parameters in Diagnosis of Oesophageal Varices Med. J. Cairo Univ., Vol. 78, No. 2, June: 105-109, 2010 www.medicaljournalofcairouniversity.com Evaluation of Clinical, Biochemical and Ultrasound Parameters in Diagnosis of Oesophageal Varices FAWZY

More information

CIRRHOSIS Definition

CIRRHOSIS Definition Cirrhosis Update Robert S. Brown, Jr., MD, MPH Vice Chair, Transitions of Care Interim Chief, Division of Gastroenterology & Hepatology Weill Cornell Medical College CIRRHOSIS Definition Irreversible fibrous

More information

Portogram shows opacification of gastroesophageal varices.

Portogram shows opacification of gastroesophageal varices. Portogram shows opacification of gastroesophageal varices. http://clinicalgate.com/radiologic-hepatobiliary-interventions/ courtesyhttp://emedicine.medscape.com/article/372708-overview DR.Thulfiqar Baiae

More information

Gastroesophageal Variceal Bleeding Successfully Controlled by Partial Splenic Embolization

Gastroesophageal Variceal Bleeding Successfully Controlled by Partial Splenic Embolization CASE REPORT Gastroesophageal Variceal Bleeding Successfully Controlled by Partial Splenic Embolization Takayuki Kogure, Jun Inoue, Eiji Kakazu, Masashi Ninomiya and Tooru Shimosegawa Abstract A 53-year-old

More information

pitfall Table 1 4 disorientation pitfall pitfall Table 1 Tel:

pitfall Table 1 4 disorientation pitfall pitfall Table 1 Tel: 11 687 692 2002 pitfall 1078 29 17 9 1 2 3 dislocation outflow block 11 1 2 3 9 1 2 3 4 disorientation pitfall 11 687 692 2002 Tel: 075-751-3606 606-8507 54 2001 8 27 2002 10 31 29 4 pitfall 16 1078 Table

More information

Impact of untreated portal vein thrombosis on pre and post liver transplant outcomes in cirrhosis

Impact of untreated portal vein thrombosis on pre and post liver transplant outcomes in cirrhosis 952 ORIGINAL ARTICLE November-December, Vol. 12 No. 6, 2013: 952-958 Impact of untreated portal vein thrombosis on pre and post liver transplant outcomes in cirrhosis John BV,* Konjeti R, Aggarwal A, Lopez

More information

Management of Cirrhotic Complications Uncontrolled Ascites. Siwaporn Chainuvati, MD Siriraj Hospital Mahidol University

Management of Cirrhotic Complications Uncontrolled Ascites. Siwaporn Chainuvati, MD Siriraj Hospital Mahidol University Management of Cirrhotic Complications Uncontrolled Ascites Siwaporn Chainuvati, MD Siriraj Hospital Mahidol University Topic Definition, pathogenesis Current therapeutic options Experimental treatments

More information

CIRROSI E IPERTENSIONE PORTALE NELLA DONNA

CIRROSI E IPERTENSIONE PORTALE NELLA DONNA Cagliari, 16 settembre 2017 CIRROSI E IPERTENSIONE PORTALE NELLA DONNA Vincenza Calvaruso, MD, PhD Ricercatore di Gastroenterologia Gastroenterologia & Epatologia, Di.Bi.M.I.S. Università degli Studi di

More information

Gastroenterology. Certification Examination Blueprint. Purpose of the exam

Gastroenterology. Certification Examination Blueprint. Purpose of the exam Gastroenterology Certification Examination Blueprint Purpose of the exam The exam is designed to evaluate the knowledge, diagnostic reasoning, and clinical judgment skills expected of the certified gastroenterologist

More information

Index. Note: Page numbers of article titles are in boldface type.

Index. Note: Page numbers of article titles are in boldface type. Index Note: Page numbers of article titles are in boldface type. A ACLF. See Acute-on-chronic liver failure (ACLF) Acute kidney injury (AKI) in ACLF patients, 967 Acute liver failure (ALF), 957 964 causes

More information

V ariceal haemorrhage is a major cause of mortality and

V ariceal haemorrhage is a major cause of mortality and 270 LIVER DISEASE The role of the transjugular intrahepatic portosystemic stent shunt (TIPSS) in the management of bleeding gastric : clinical and haemodynamic correlations D Tripathi, G Therapondos, E

More information

Hepatocytes produce. Proteins Clotting factors Hormones. Bile Flow

Hepatocytes produce. Proteins Clotting factors Hormones. Bile Flow R.J.Bailey MD Hepatocytes produce Proteins Clotting factors Hormones Bile Flow Trouble.. for the liver! Trouble for the Liver Liver Gall Bladder Common Alcohol Hep C Fatty Liver Cancer Drugs Viruses Uncommon

More information

Cruveilhier-Baumgarten syndrome: anatomical and pathologic imaging of periumbilical venous network

Cruveilhier-Baumgarten syndrome: anatomical and pathologic imaging of periumbilical venous network Cruveilhier-Baumgarten syndrome: anatomical and pathologic imaging of periumbilical venous network Poster No.: C-0442 Congress: ECR 2014 Type: Educational Exhibit Authors: J. Isogai, H. Sakamoto ; Asahi/JP,

More information

GASTROENTEROLOGY Maintenance of Certification (MOC) Examination Blueprint

GASTROENTEROLOGY Maintenance of Certification (MOC) Examination Blueprint GASTROENTEROLOGY Maintenance of Certification (MOC) Examination Blueprint ABIM invites diplomates to help develop the Gastroenterology MOC exam blueprint Based on feedback from physicians that MOC assessments

More information

Ascites Management. Atif Zaman, MD MPH Oregon Health & Science University Professor of Medicine Division of Gastroenterology and Hepatology

Ascites Management. Atif Zaman, MD MPH Oregon Health & Science University Professor of Medicine Division of Gastroenterology and Hepatology Ascites Management Atif Zaman, MD MPH Oregon Health & Science University Professor of Medicine Division of Gastroenterology and Hepatology Disclosure 1. The speaker Atif Zaman, MD MPH have no relevant

More information

AASLD PRACTICE GUIDELINE. The Role of Transjugular Intrahepatic Portosystemic Shunt in the Management of Portal Hypertension. Preamble.

AASLD PRACTICE GUIDELINE. The Role of Transjugular Intrahepatic Portosystemic Shunt in the Management of Portal Hypertension. Preamble. AASLD PRACTICE GUIDELINE The Role of Transjugular Intrahepatic Portosystemic Shunt in the Management of Portal Hypertension Thomas D. Boyer 1 and Ziv J. Haskal 2 Preamble The recommendations in this article

More information

Invasive Evaluation of Portal Hypertension. Vincenzo La Mura, MD PhD Department of Biomedical Sciences for Health University of Milan

Invasive Evaluation of Portal Hypertension. Vincenzo La Mura, MD PhD Department of Biomedical Sciences for Health University of Milan Invasive Evaluation of Portal Hypertension Vincenzo La Mura, MD PhD Department of Biomedical Sciences for Health University of Milan Vincenzo La Mura, MD, PhD Dipartimento di scienze Biomediche per la

More information

DISEASE LEVEL MEDICAL EVIDENCE PROTOCOL

DISEASE LEVEL MEDICAL EVIDENCE PROTOCOL DISEASE LEVEL MEDICAL EVIDENCE PROTOCOL 1. This Protocol sets out the medical evidence that must be delivered to the Administrator for proof of Disease Level. It is subject to such further and other Protocols

More information

The role of ultrasonography in the evaluation of portal hemodynamics in healthy adults and pathologic conditions

The role of ultrasonography in the evaluation of portal hemodynamics in healthy adults and pathologic conditions ARS Medica Tomitana - 2016; 2(22): 128-134 10.1515/arsm-2016-0022 Achim C. Anda 1, Bordei P. 1, Dumitru E. 1,2 The role of ultrasonography in the evaluation of portal hemodynamics in healthy adults and

More information

بسم الله الرحمن الرحيم أوتيتم من العلم إال قليال وما

بسم الله الرحمن الرحيم أوتيتم من العلم إال قليال وما بسم الله الرحمن الرحيم أوتيتم من العلم إال قليال وما 1 2 Goals of the Lecture: What is the portal vein? How common is PVT? What conditions are associated with PVT? How does patient with PVT present? How

More information

Small Plicae Circularis. Short Closely packed together. Sparse, completely absent at distal part Lymphoid Nodule

Small Plicae Circularis. Short Closely packed together. Sparse, completely absent at distal part Lymphoid Nodule Intestines Differences Between Jejunum and Ileum Types Jejunum Ileum Color Deeper red Paler pink Calibre Bigger Smaller Thickness of wall Thick and Heavy Thin and Lighter Vascularity Highly vascularised

More information

Prevalence and outcome of portal thrombosis in a cohort of cirrhotic patients undergoing liver transplantation

Prevalence and outcome of portal thrombosis in a cohort of cirrhotic patients undergoing liver transplantation 1130-0108/2016/108/11/716-720 Revista Española de Enfermedades Digestivas Copyright 2016. SEPD y ARÁN EDICIONES, S.L. Rev Esp Enferm Dig 2016, Vol. 108, N.º 11, pp. 716-720 ORIGINAL PAPERS Prevalence and

More information

Intrahepatic Cholangiocarcinoma (ICC) Detected by Sonography

Intrahepatic Cholangiocarcinoma (ICC) Detected by Sonography 661245JDMXXX10.1177/8756479316661245Journal of Diagnostic Medical SonographyHamer research-article2016 Case Study Intrahepatic Cholangiocarcinoma (ICC) Detected by Sonography Journal of Diagnostic Medical

More information

Risk factors for 5-day bleeding after endoscopic treatments for gastroesophageal varices in liver cirrhosis

Risk factors for 5-day bleeding after endoscopic treatments for gastroesophageal varices in liver cirrhosis Original Article Page 1 of 9 Risk factors for 5-day bleeding after endoscopic treatments for gastroesophageal varices in liver cirrhosis Rui Sun*, Xingshun Qi* #, Deli Zou, Xiaodong Shao, Hongyu Li, Xiaozhong

More information

Prognosis of untreated Primary Sclerosing Cholangitis (PSC) Erik Christensen Copenhagen, Denmark

Prognosis of untreated Primary Sclerosing Cholangitis (PSC) Erik Christensen Copenhagen, Denmark Prognosis of untreated Primary Sclerosing Cholangitis (PSC) Erik Christensen Copenhagen, Denmark Study of Prognosis of PSC Difficulties: Disease is rare The duration of the course of disease may be very

More information

Causes of Liver Disease in US

Causes of Liver Disease in US Learning Objectives Updates in Outpatient Cirrhosis Management Jennifer Guy, MD MAS Director, Liver Cancer Program California Pacific Medical Center guyj@sutterhealth.org Review cirrhosis epidemiology,

More information

Indications, results and benefits of the measurement of hepatic venous pressure gradient

Indications, results and benefits of the measurement of hepatic venous pressure gradient Indications, results and benefits of the measurement of hepatic venous pressure gradient Poster No.: C-0976 Congress: ECR 2017 Type: Scientific Exhibit Authors: J. P. León Salinas 1, M. D. Ferrer-Puchol

More information

Collateral Pathways in Budd Chiari Syndrome- MDCT Depiction

Collateral Pathways in Budd Chiari Syndrome- MDCT Depiction Review Article imedpub Journals http://www.imedpub.com/ http://dx.doi.org/10.4172/ijdd.1000025 Collateral Pathways in Budd Chiari Syndrome- MDCT Depiction Abstract Budd Chiari syndrome (BCS) is a condition

More information

Original Article Gastrointestinal Imaging

Original Article Gastrointestinal Imaging Original Article Gastrointestinal Imaging https://doi.org/10.3348/kjr.2018.19.1.32 pissn 1229-6929 eissn 2005-8330 Korean J Radiol 2018;19(1):32-39 Left Gastric Vein Visualization with Hepatopetal Flow

More information

Liver Transplantation for Alcoholic Liver Disease in the United States: 1988 to 1995

Liver Transplantation for Alcoholic Liver Disease in the United States: 1988 to 1995 Liver Transplantation for Alcoholic Liver Disease in the United States: 1988 to 1995 Steven H. Belle, Kimberly C. Beringer, and Katherine M. Detre T he Scientific Liver Transplant Registry (LTR) was established

More information

The current recommended prophylaxis of variceal. Long-Term Follow-up of Hemodynamic Responders to Pharmacological Therapy After Variceal Bleeding

The current recommended prophylaxis of variceal. Long-Term Follow-up of Hemodynamic Responders to Pharmacological Therapy After Variceal Bleeding Long-Term Follow-up of Hemodynamic Responders to Pharmacological Therapy After Variceal Bleeding Salvador Augustin, 1 Antonio Gonzalez, 1 Laia Badia, 1 Laura Millan, 1 Aranzazu Gelabert, 2 Alejandro Romero,

More information

CT Signs of Hepatofugal Portal Venous Flow in Patients with Cirrhosis

CT Signs of Hepatofugal Portal Venous Flow in Patients with Cirrhosis Thomas J. Bryce Benjamin M. Yeh Aliya Qayyum Preeyacha Pacharn 2 Nathan M. Bass 3 Ying Lu Fergus V. Coakley Received April, 23; accepted after revision June 26, 23. Department of Medicine and Department

More information

Systemic Inflammatory Response Syndrome and MELD Score in Hospital Outcome of Patients with Liver Cirrhosis

Systemic Inflammatory Response Syndrome and MELD Score in Hospital Outcome of Patients with Liver Cirrhosis 168 Original Article Systemic Inflammatory Response Syndrome and MELD Score in Hospital Outcome of Patients with Liver Cirrhosis Ramin Behroozian 1*, Mehrdad Bayazidchi 1, Javad Rasooli 1 1. Department

More information

Role of colour doppler sonography in evaluation of portal venous hypertension

Role of colour doppler sonography in evaluation of portal venous hypertension Original Research Article Role of colour doppler sonography in evaluation of portal venous hypertension Rajani Gorantla 1, G V N Pradeep 2*, K Suseel Kumar 3 1,2 Assistant Professor, Department of Radiodiagnosis,

More information